Pathstone Family Office’s PDL BioPharma, Inc. PDLI Stock Holding History

Pathstone Family Office’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-209	Closed	–	–	721
2017 Q1	$0	Buy	+209	New	+$462	﹤0.01%	654

Other funds holding PDLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Pathstone Family Office's PDLI Position: Q2 2017 in Review

Pathstone Family Office sold out of PDL BioPharma, Inc. (PDLI) in Q2 2017, closing a stake of 209 shares.

Pathstone Family Office first reported a position in PDLI in Q1 2017 and held it in 1 quarter. The position peaked at $0 in Q1 2017. 171 funds tracked by Wall St. Rank hold PDLI as of Q2 2017.

Pathstone Family Office reported no remaining PDL BioPharma, Inc. position as of Q2 2017 after selling out during the quarter.
Pathstone Family Office sold 209 PDL BioPharma, Inc. shares in Q2 2017.
Pathstone Family Office first reported a position in PDL BioPharma, Inc. in Q1 2017 and held it in 1 quarter.
Pathstone Family Office's PDL BioPharma, Inc. position peaked at $0 in Q1 2017.
171 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q2 2017.

Based on Pathstone Family Office's 13F filing for Q2 2017, filed 11 Aug 2017.